lems. Subtotal tumour resection with radiotherapy is an alternative treatment.

The differential diagnosis of growth failure is broad, and making a diagnosis can be challenging, especially when the presenting symptoms are nonspecific (Box 1). This case illustrates the importance of considering central nervous system pathology in children with growth failure, especially when it is accompanied by symptoms of headache and vomiting.

Chantelle Barnard
Division of Hospital Pediatrics
Department of Pediatrics
Alberta Children’s Hospital
Calgary, Alta.

Jeremy N. Friedman
Division of Pediatric Medicine
Department of Pediatrics
Faculty of Medicine
University of Toronto
Hospital for Sick Children
Toronto, Ont.

Competing interests: None declared.

REFERENCES
1. Behrman R. Nelson textbook of pediatrics. 17th ed. London: Saunders; 2003. p. 133-4, 1702-7, 1854.
2. Thomsett MJ, Conte FA, Kaplan SL, et al. Endocrine and neurologic outcomes in childhood craniopharyngioma: review of effect of treatment in 42 patients. J Pediatr 1980;97:728-35.
3. Sklar CA. Craniopharyngioma: Endocrine abnormalities at presentation. Pediatr Neurosurg 1994; 21(suppl 1):18-20.

Box 1: Who is working on malaria-related issues?
• Roll Back Malaria (RBM):
www.rbm.who.int
• Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM):
www.theglobalfund.org
• Bill and Melinda Gates Foundation:
www.gatesfoundation.org
• PATH Malaria Vaccine Initiative (MVI):
www.malarialogue.org
• Medicines for Malaria Venture (MMV):
www.mmv.org
• Multilateral Initiative on Malaria (MIM):
www.mim.nih.org
• Drugs for Neglected Diseases Initiative (DNDi)
• Malaria R&D Alliance:
www.malariaalliance.org

PUBLIC HEALTH
Taking away the sting of malaria

More than 40% of the world’s population is at risk of malaria, and more than a million people die of it each year. Malaria kills a child every 30 seconds; 90% of people who die from malaria are children not yet 5 years of age, and most (90%) of these deaths take place in sub-Saharan Africa.1

Where malaria is endemic, related illness and death have severe economic as well as human costs. It is estimated that US$12 billion is lost in Africa each year to the costs of care and reduced productivity, and that a high endemic malaria burden lowers the growth of a country’s annual GNP (gross national product) by 2%.1

Currently, affected countries are beset by limited access to rapid diagnostic tests and to the resources required to support prevention strategies and overcome drug resistance. Turning the malaria problem around requires an ongoing multipronged attack emphasizing both prevention and treatment.

Malaria is commonly diagnosed and treated according to clinical symptoms rather than laboratory test results; the result of this is that many of the people treated may not in fact be infected. Appropriate diagnosis is limited by a lack of laboratory services, or services of poor quality; and although rapid tests (which are currently effective for Plasmodium falciparum infections only) are available, they are not widely accessible because of their cost.1 The lack of good diagnostic tests increases drug use (and costs), and contributes to more rapid development of drug resistance.2

The treatment of malaria has also become increasingly problematic. Common and sequential use of monotherapies and reliance on quinoline and antifolate compounds have contributed to a burgeoning problem of drug resistance.1,2 In an effort to combat ineffective treatment, the World Health Organization (WHO) has recommended that all countries where resistance to conventional monotherapies such as chloroquine or amodiaquine is common or growing use combination therapies (CTs), preferably ones containing artemisinin derivatives (ACTs). As an indication to switch to ACTs, WHO has also lowered the endemic resistance threshold from 25% to 15% among children younger than 5 years.2

WHO’s change in recommendation follows evidence that ACTs are well tolerated, produce rapid therapeutic responses, are effective against P. falciparum and can cure infections after just 3 days of treatment.3 They also reduce gametocyte carriage and may therefore reduce malaria transmission. To improve ease of use, a fixed-dose combination (2 drugs combined in one pill) and dissolvable pills for children are being developed.

Despite clear indications for their use, in 2005 ACTs were used in the public sectors of only 9 countries in Africa. This is partly due to increased cost: ACTs cost 10 times that of older therapies.1 Although the Global Fund for Fighting AIDS, Tuberculosis and Malaria, the largest funder of ACTs in developing countries, has committed US$41 million for ACT purchases, the
cost of estimated global requirements (132 million courses, in 2005) far exceeds the funding available.2 The decision to encourage many African countries at once to change to ACTs has also led to global shortages of the drugs, a problem exacerbated by the 6 months of cultivation needed for Artemisia annua plants plus the time required for processing and manufacturing.1

In the meantime, prevention efforts are continuing. Bed nets are being widely promoted, although mass distribution is difficult. In Africa, 30 million nets per year are currently required to meet the target of having 60% of at-risk populations, including young children and pregnant women, protected by nets within 3 years.3 Insecticidal bed nets are being developed that last for 4–5 years without requiring retreatment with insecticide, which would improve prevention efforts.

Intermittent treatment regimens are also recommended for pregnant women to prevent malarial episodes. Pregnant women are particularly vulnerable because of their lowered immunity. Intermittent treatment, involving at least 2 preventive treatments with an effective antimalarial drug during antenatal clinic visits, has been shown to reduce the number of infants with low birth weights.3

Finally, clinical trials of malaria vaccines are underway, and new insecticides that are safe for the environment and for people are being developed for larval control.

Current challenges facing malaria control are not new. The battle to control malaria at a global level began with WHO’s vector-control programs in the 1950s; as mortality rates rose, WHO introduced the Roll Back Malaria (RBM) program in 1998. Now, other international partners (Box 1) are supporting the development of effective diagnostics, treatment (Box 2) and global management of malaria. It is now up to WHO and its partners to make sure the prevention and treatment objectives outlined in the UN Millennium Development Goals and the 2000 African leaders’ summit (Box 3) are met: appropriate and quick prevention, accessible prevention measures and effective epidemic control.

Sally Murray
Editorial Fellow
CMAJ

REFERENCES
1. Greenwood BM, Bojang K, Whitty C, et al. Malaria. Lancet 2005; 365:1487–8.
2. World Health Organization. Roll back malaria: facts on artemisinin-based combination therapies. Geneva: WHO; 2005. Available: www.rbm.who.int/cmc_upload/0/000/015/364/RBMInfosheet_9.htm (accessed 2005 Dec 8).
3. Global Fund for Fighting AIDS, Tuberculosis and Malaria (GFATM). HIV/AIDS, tuberculosis and malaria: the status and impact of the three diseases. Geneva: GFATM; 2005.

LEADERSHIP
CMAJ is a founding member of the International Committee of Medical Journal Editors, an organization that is devoted to ensuring the highest integrity in scientific publishing and is a driving force in the mandatory registration of clinical trials.